文|翠鸟资本曾因新冠疫苗在全球供应超28亿剂、年净利润高达近千亿元人民币的“疫苗之王”——科兴生物（SVA.0），在停牌六年后最终黯然退场。更令人震惊的是，就在退市前夕，公司启动了总额近90亿美元的“清仓式”分红，股息率高达850%。这一场闹剧似的退市原因复杂，既有让人难以理解的短视和贪婪，也有内斗引发的治理危机。但最终结果，是一家本可跻身全球医药龙头的企业陷入深渊，背后原因，惹人深思。11月12...
Source Link文|翠鸟资本曾因新冠疫苗在全球供应超28亿剂、年净利润高达近千亿元人民币的“疫苗之王”——科兴生物（SVA.0），在停牌六年后最终黯然退场。更令人震惊的是，就在退市前夕，公司启动了总额近90亿美元的“清仓式”分红，股息率高达850%。这一场闹剧似的退市原因复杂，既有让人难以理解的短视和贪婪，也有内斗引发的治理危机。但最终结果，是一家本可跻身全球医药龙头的企业陷入深渊，背后原因，惹人深思。11月12...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.